ArticlePharmacological reports : PR2026
Adverse events during cystic fibrosis transmembrane conductance regulator modulator therapy in children with cystic fibrosis: an observational study.
Marta Osińska et al.PubMed ↗Publisher ↗
No numbers read from the abstract.